vs
Side-by-side financial comparison of Lilly (Eli) (LLY) and Travelers Companies (The) (TRV). Click either name above to swap in a different company.
Lilly (Eli) is the larger business by last-quarter revenue ($19.3B vs $12.4B, roughly 1.6× Travelers Companies (The)). Lilly (Eli) runs the higher net margin — 34.4% vs 20.1%, a 14.3% gap on every dollar of revenue. On growth, Lilly (Eli) posted the faster year-over-year revenue change (42.6% vs 3.5%). Over the past eight quarters, Lilly (Eli)'s revenue compounded faster (48.3% CAGR vs 5.2%).
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The Travelers Companies, Inc., commonly known as Travelers, is an American multinational insurance company. It is the second-largest writer of U.S. commercial property and casualty insurance, and the sixth-largest writer of U.S. personal insurance through independent agents. Travelers is incorporated in Minnesota, with headquarters in New York City, and its largest office in Hartford, Connecticut. It has been a component of the Dow Jones Industrial Average since June 8, 2009.
LLY vs TRV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.3B | $12.4B |
| Net Profit | $6.6B | $2.5B |
| Gross Margin | 82.5% | — |
| Operating Margin | 42.8% | 25.0% |
| Net Margin | 34.4% | 20.1% |
| Revenue YoY | 42.6% | 3.5% |
| Net Profit YoY | 50.5% | 19.9% |
| EPS (diluted) | $7.39 | $10.96 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $19.3B | $12.4B | ||
| Q3 25 | $17.6B | $12.5B | ||
| Q2 25 | $15.6B | $12.1B | ||
| Q1 25 | $12.7B | $11.8B | ||
| Q4 24 | $13.5B | $12.0B | ||
| Q3 24 | $11.4B | $11.9B | ||
| Q2 24 | $11.3B | $11.3B | ||
| Q1 24 | $8.8B | $11.2B |
| Q4 25 | $6.6B | $2.5B | ||
| Q3 25 | $5.6B | $1.9B | ||
| Q2 25 | $5.7B | $1.5B | ||
| Q1 25 | $2.8B | $395.0M | ||
| Q4 24 | $4.4B | $2.1B | ||
| Q3 24 | $970.3M | $1.3B | ||
| Q2 24 | $3.0B | $534.0M | ||
| Q1 24 | $2.2B | $1.1B |
| Q4 25 | 82.5% | — | ||
| Q3 25 | 82.9% | — | ||
| Q2 25 | 84.3% | — | ||
| Q1 25 | 82.5% | — | ||
| Q4 24 | 82.2% | — | ||
| Q3 24 | 81.0% | — | ||
| Q2 24 | 80.8% | — | ||
| Q1 24 | 80.9% | — |
| Q4 25 | 42.8% | 25.0% | ||
| Q3 25 | 41.1% | 18.8% | ||
| Q2 25 | 43.6% | 15.5% | ||
| Q1 25 | 27.2% | 4.0% | ||
| Q4 24 | 37.2% | 21.6% | ||
| Q3 24 | 13.9% | 13.1% | ||
| Q2 24 | 31.1% | 5.8% | ||
| Q1 24 | 28.9% | 12.2% |
| Q4 25 | 34.4% | 20.1% | ||
| Q3 25 | 31.7% | 15.1% | ||
| Q2 25 | 36.4% | 12.5% | ||
| Q1 25 | 21.7% | 3.3% | ||
| Q4 24 | 32.6% | 17.3% | ||
| Q3 24 | 8.5% | 10.6% | ||
| Q2 24 | 26.3% | 4.7% | ||
| Q1 24 | 25.6% | 10.0% |
| Q4 25 | $7.39 | $10.96 | ||
| Q3 25 | $6.21 | $8.24 | ||
| Q2 25 | $6.29 | $6.53 | ||
| Q1 25 | $3.06 | $1.70 | ||
| Q4 24 | $4.88 | $8.96 | ||
| Q3 24 | $1.07 | $5.42 | ||
| Q2 24 | $3.28 | $2.29 | ||
| Q1 24 | $2.48 | $4.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.3B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5B | $32.9B |
| Total Assets | $112.5B | $143.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.3B | — | ||
| Q3 25 | $9.9B | — | ||
| Q2 25 | $3.5B | — | ||
| Q1 25 | $3.2B | — | ||
| Q4 24 | $3.4B | — | ||
| Q3 24 | $3.5B | — | ||
| Q2 24 | $3.4B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $29.5B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $26.5B | $32.9B | ||
| Q3 25 | $23.8B | $31.6B | ||
| Q2 25 | $18.3B | $29.5B | ||
| Q1 25 | $15.8B | $28.2B | ||
| Q4 24 | $14.2B | $27.9B | ||
| Q3 24 | $14.2B | $27.7B | ||
| Q2 24 | $13.6B | $24.9B | ||
| Q1 24 | $12.8B | $25.0B |
| Q4 25 | $112.5B | $143.7B | ||
| Q3 25 | $114.9B | $143.7B | ||
| Q2 25 | $100.9B | $138.9B | ||
| Q1 25 | $89.4B | $136.0B | ||
| Q4 24 | $78.7B | $133.2B | ||
| Q3 24 | $75.6B | $134.6B | ||
| Q2 24 | $71.9B | $129.3B | ||
| Q1 24 | $63.9B | $127.4B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.08× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.2B | $2.7B |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.49× | 1.08× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.2B | $2.7B | ||
| Q3 25 | $8.8B | $4.2B | ||
| Q2 25 | $3.1B | $2.3B | ||
| Q1 25 | $1.7B | $1.4B | ||
| Q4 24 | $2.5B | $2.1B | ||
| Q3 24 | $3.7B | $3.9B | ||
| Q2 24 | $1.5B | $1.7B | ||
| Q1 24 | $1.2B | $1.5B |
| Q4 25 | 0.49× | 1.08× | ||
| Q3 25 | 1.58× | 2.24× | ||
| Q2 25 | 0.55× | 1.55× | ||
| Q1 25 | 0.60× | 3.44× | ||
| Q4 24 | 0.56× | 0.99× | ||
| Q3 24 | 3.83× | 3.08× | ||
| Q2 24 | 0.49× | 3.14× | ||
| Q1 24 | 0.52× | 1.30× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LLY
| Other | $5.4B | 28% |
| Zepbound | $4.2B | 22% |
| Mounjaro | $4.1B | 21% |
| Verzenio | $997.1M | 5% |
| Collaborationand Other Revenue | $991.7M | 5% |
| Taltz | $724.3M | 4% |
| Trulicity | $692.8M | 4% |
| Other Cardiometabolic Health | $524.5M | 3% |
| Other Oncology | $514.8M | 3% |
| Jardiance | $465.8M | 2% |
| Neuroscience | $320.2M | 2% |
| Other Immunology | $187.3M | 1% |
| Other Product Total | $77.0M | 0% |
TRV
| Business And International Insurance | $6.6B | 53% |
| Personal Insurance | $4.6B | 37% |
| Bond And Specialty Insurance | $1.2B | 9% |
